Trevi Therapeutics, Inc.
TRVI
$13.35
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.59% | 18.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.41% | 19.63% | |||
| Operating Income | -1.41% | -19.63% | |||
| Income Before Tax | 4.10% | -19.04% | |||
| Income Tax Expenses | 28.57% | -90.91% | |||
| Earnings from Continuing Operations | 4.06% | -18.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.06% | -18.97% | |||
| EBIT | -1.41% | -19.63% | |||
| EBITDA | -1.42% | -19.69% | |||
| EPS Basic | 13.88% | -7.39% | |||
| Normalized Basic EPS | 13.87% | -7.45% | |||
| EPS Diluted | 13.88% | -7.39% | |||
| Normalized Diluted EPS | 13.87% | -7.45% | |||
| Average Basic Shares Outstanding | 11.32% | 10.83% | |||
| Average Diluted Shares Outstanding | 11.32% | 10.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||